CJC-1295 (no DAC) 10mg — Research Protocol Reference

CJC-1295 (No DAC) is administered via subcutaneous injection twice daily throughout the active cycle.

Timing both injections to align with the body's natural GH secretion windows produces the strongest response, once before bed to amplify the nocturnal GH pulse, and once in the morning fasted or immediately post-training to capture the exercise-driven pulse. The short half-life of approximately 30 minutes means each injection fires and clears quickly, so injection timing relative to sleep and training is the most important dosing variable.

Do not use CJC-1295 No DAC if you have active malignancy, diabetic retinopathy, or hypersensitivity to GHRH analogues. Monitor fasting glucose during the active cycle, elevated GH can reduce insulin sensitivity, particularly at higher doses or during prolonged cycles.

CJC-1295 No DAC is a GHRH analogue with a half-life of approximately 30 minutes, producing a sharp pulsatile GH release that mirrors the body's natural secretion pattern. Published research documents significant GH and IGF-1 elevation following subcutaneous administration at 100–300mcg per injection. The twice-daily dosing frequency is required to maintain meaningful GH stimulation across the day, the short half-life means a single daily dose produces only one GH pulse, which is insufficient for the sustained IGF-1 elevation that drives body composition and recovery benefits. The 4-week rest period allows the pituitary to restore baseline GH sensitivity before the next cycle. At 3mL BAC, concentration is 3,333mcg/mL, all draws are approximate and a 3mL micro needle is required throughout.

In biohacking forums, CJC-1295 No DAC is almost universally stacked with Ipamorelin at a 1:1 ratio and dosed twice daily, once before bed and once fasted in the morning or post-training. Solo use without a GHRP is considered suboptimal by most community protocols, as CJC-1295 No DAC requires an endogenous GH pulse to amplify for maximum effect. These are community-derived patterns, not clinical.

CJC-1295 No DAC is injected subcutaneously twice daily. Both injection windows are tied to GH secretion biology, timing matters more here than with most peptides.

• Dose 1, before bed (primary dose): The largest natural GH pulse occurs 60–90 minutes after sleep onset. Injecting 15–30 minutes before bed positions the CJC-1295 No DAC peak to overlap with this nocturnal pulse, amplifying the recovery and repair benefits of sleep-driven GH secretion.
• Dose 2, fasted morning or immediately post-training: A fasted state and exercise are the two strongest natural GH triggers. Injecting on an empty stomach in the morning, or within 15 minutes of finishing a training session, captures the exercise-driven GH window for maximum anabolic and lipolytic effect.
• Avoid dosing within 2 hours of a high-carbohydrate meal: Elevated insulin suppresses GH secretion directly. Injecting CJC-1295 No DAC in an insulin-elevated state significantly reduces the GH response. Keep both injection windows in a fasted or low-insulin state wherever possible.
• Draw each dose fresh: Do not pre-draw doses into syringes for later use. Draw at injection time from the refrigerated vial each session.
• Rotate injection sites every session: With twice-daily dosing across a 12-week cycle, consistent rotation across the abdomen and outer thighs is essential to avoid site irritation and lipodystrophy.

• Stack with Ipamorelin for best results: CJC-1295 No DAC stimulates the GHRH receptor, it amplifies an existing GH pulse. Ipamorelin activates the ghrelin receptor and triggers its own GH pulse independently. Together they hit two separate pathways simultaneously, producing a GH release significantly greater than either alone. The standard stack ratio is 1:1 at the same dose and timing.
• Fasted state at both injection windows is not optional: Insulin is the primary suppressor of GH secretion. Dosing in a fed state, particularly after carbohydrates, significantly blunts the GH response and reduces the value of the injection.
• Effects build over weeks, not days: IGF-1 elevation is cumulative. Meaningful body composition and recovery changes typically become apparent at weeks 4–6. Do not adjust dose prematurely based on early cycle response.
• Monitor fasting glucose at weeks 4 and 8: Sustained GH elevation reduces insulin sensitivity in some individuals. A bloodwork check mid-cycle catches any glucose dysregulation before it becomes an issue.
• Discard at 28–30 days post-reconstitution. With twice-daily dosing at 200mcg, a 10mg vial provides approximately 25 injection pairs, well within the 28–30 day window.

Taking too much CJC-1295 (No DAC) can increase side effects. Signs your dose may be too high:

• Water retention and puffiness: The most common above-range sign. GH drives fluid retention, particularly in the hands, feet, and face. Reduce to 200mcg per injection if persistent beyond the first two weeks.
• Joint pain or carpal tunnel symptoms: Elevated GH causes fluid accumulation in joint capsules. Tingling or numbness in the hands is a reliable signal to reduce dose immediately.
• Fatigue or lethargy: Paradoxical fatigue at higher doses is a documented GH effect. Reduce to the previous dose step and allow one week to normalise.
• Elevated fasting glucose: GH reduces insulin sensitivity at above-range doses. If fasting glucose rises above personal baseline, reduce dose and recheck within two weeks.
• Injection site redness or irritation not resolving within 24 hours: Reduce volume per injection and rotate sites more consistently.

If any of these occur, reduce to 100mcg per injection and hold for one week before attempting to advance again.

A dose may be too low if expected effects are absent after consistent use. Common indicators:

• No improvement in sleep quality or recovery after 3–4 weeks at maintenance: Confirm both injection windows are fasted and timed correctly before adjusting dose. Sleep improvement is typically the earliest indicator of a working protocol.
• No change in body composition after 6 weeks at 200mcg twice daily: Confirm injection technique, fasted timing, and that both doses are being administered consistently. If all confirmed, advancing to 300mcg per injection is within the documented range.
• No water retention at all in the first two weeks: Mild transient fluid retention is expected at therapeutic doses. Complete absence alongside no other effects may indicate underdosing or technique issues, confirm micro needle draw accuracy before adjusting.

If these indicators persist after a full 6-week maintenance phase with correct timing and technique, advancing to 300mcg (~9 units) per injection for the remainder of the cycle is appropriate.

⚠️ This is for informational purposes only. For medical advice or diagnosis, consult a professional. ⚠️